CY1113825T1 - Υδατικα εναιωρηματα ριλουζολης - Google Patents

Υδατικα εναιωρηματα ριλουζολης

Info

Publication number
CY1113825T1
CY1113825T1 CY20131100136T CY131100136T CY1113825T1 CY 1113825 T1 CY1113825 T1 CY 1113825T1 CY 20131100136 T CY20131100136 T CY 20131100136T CY 131100136 T CY131100136 T CY 131100136T CY 1113825 T1 CY1113825 T1 CY 1113825T1
Authority
CY
Cyprus
Prior art keywords
suspensions
riluzole
rusluzole
aquatic
aqueous
Prior art date
Application number
CY20131100136T
Other languages
English (en)
Inventor
Roberta Artico
Marco Adami
Daniele Barbareschi
Jaime Moscoso
Tiziano Oldoni
Paolo Mascagni
Original Assignee
Italfarmaco S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113825(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco S.P.A. filed Critical Italfarmaco S.P.A.
Publication of CY1113825T1 publication Critical patent/CY1113825T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Φυσικά και χημικά σταθερά υδατικά εναιωρήματα ριλουζόλης αποκαλύπτονται μαζί με τις μεθόδους παρασκευής αυτών. Τέτοια υδατικά εναιωρήματα περιλαμβάνουν ριλουζόλη σε μορφή σωματιδίων και τουλάχιστον ένα μέσον ύγρανσης, κατά προτίμηση ένα επιφανειοδραστικό. Η ριλουζόλη απαντά σε ποσότητες από περίπου 0,1% έως περίπου 20% w/v και έχει ένα μέσο μέγεθος σωματιδίου μικρότερο από 200 μm, τέτοια εναιωρήματα είναι απαλλαγμένα από τις γνωστές τοπικές (στοματικές) επιδράσεις της ριλουζόλης.
CY20131100136T 2009-03-13 2013-02-14 Υδατικα εναιωρηματα ριλουζολης CY1113825T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425101A EP2228054A1 (en) 2009-03-13 2009-03-13 Riluzole aqueous suspensions
EP10706234A EP2405890B1 (en) 2009-03-13 2010-03-02 Riluzole aqueous suspensions

Publications (1)

Publication Number Publication Date
CY1113825T1 true CY1113825T1 (el) 2016-07-27

Family

ID=40810549

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100136T CY1113825T1 (el) 2009-03-13 2013-02-14 Υδατικα εναιωρηματα ριλουζολης

Country Status (22)

Country Link
US (1) US8765150B2 (el)
EP (2) EP2228054A1 (el)
JP (1) JP5607083B2 (el)
KR (1) KR101680175B1 (el)
CN (1) CN102341091B (el)
BR (1) BRPI1006418A2 (el)
CA (1) CA2748856C (el)
CL (1) CL2011002217A1 (el)
CO (1) CO6410281A2 (el)
CY (1) CY1113825T1 (el)
DK (1) DK2405890T3 (el)
ES (1) ES2400349T3 (el)
HK (1) HK1161985A1 (el)
HR (1) HRP20130021T1 (el)
MX (1) MX2011008922A (el)
PE (1) PE20120649A1 (el)
PL (1) PL2405890T3 (el)
PT (1) PT2405890E (el)
RU (1) RU2498802C2 (el)
SI (1) SI2405890T1 (el)
SM (1) SMT201300022B (el)
WO (1) WO2010102923A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849213A1 (en) * 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination of riluzole and ck-2017357 for treating als
WO2013192610A2 (en) * 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
DK3023093T3 (da) * 2014-11-20 2017-11-06 S I I T S R L -Servizio Int Imballaggi Termosaldanti Medicinsk præparat på basis af diosmectit
ES2882783T3 (es) * 2014-11-21 2021-12-02 Biohaven Pharm Holding Co Ltd Formulación sublingual de riluzol
EP3220890A1 (en) * 2014-11-21 2017-09-27 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105726477B (zh) * 2016-03-01 2018-10-12 山东司邦得制药有限公司 一种小儿多潘立酮混悬液及其制备方法
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
WO2019108594A1 (en) * 2017-11-28 2019-06-06 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
CN111437256A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种利鲁唑缓释口服混悬液
CN115025056A (zh) * 2022-06-27 2022-09-09 郑州大学第一附属医院 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282950B6 (sk) 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1552831B1 (en) * 1999-06-04 2009-01-07 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for treating multiple sclerosis
AU770879B2 (en) 1999-08-12 2004-03-04 Eli Lilly And Company Ectoparasiticidal aqueous suspension formulations of spinosyns
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6432992B1 (en) 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
ES2269858T3 (es) * 2003-04-28 2007-04-01 Biofrontera Bioscience Gmbh Utilizacion de riluzol combinado con sustancias auxiliares y aditivos adecuados pra el tratamiento de enfermedades, caracterizadas una hiperproliferacion de queratinocitos, en particular neurodermitis y psoriasis.
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
UA41879U (ru) * 2009-02-03 2009-06-10 Сергей Викторович Фурс Инфракрасный обогревательный прибор

Also Published As

Publication number Publication date
BRPI1006418A2 (pt) 2016-11-29
US20120039953A1 (en) 2012-02-16
PT2405890E (pt) 2013-02-20
US8765150B2 (en) 2014-07-01
KR20120003854A (ko) 2012-01-11
SMT201300022B (it) 2013-03-08
WO2010102923A2 (en) 2010-09-16
HK1161985A1 (en) 2012-08-17
PL2405890T3 (pl) 2013-04-30
RU2498802C2 (ru) 2013-11-20
CA2748856A1 (en) 2010-09-16
JP5607083B2 (ja) 2014-10-15
KR101680175B1 (ko) 2016-11-28
EP2405890A2 (en) 2012-01-18
ES2400349T3 (es) 2013-04-09
WO2010102923A3 (en) 2011-03-03
EP2405890B1 (en) 2012-11-28
DK2405890T3 (da) 2013-02-04
RU2011141422A (ru) 2013-04-20
SI2405890T1 (sl) 2013-02-28
CL2011002217A1 (es) 2012-03-09
CN102341091A (zh) 2012-02-01
EP2228054A1 (en) 2010-09-15
CO6410281A2 (es) 2012-03-30
CN102341091B (zh) 2013-08-07
PE20120649A1 (es) 2012-06-07
MX2011008922A (es) 2011-12-06
JP2012520254A (ja) 2012-09-06
CA2748856C (en) 2017-01-03
HRP20130021T1 (hr) 2013-02-28

Similar Documents

Publication Publication Date Title
CY1113825T1 (el) Υδατικα εναιωρηματα ριλουζολης
EA201101332A1 (ru) Составы
CY1120585T1 (el) Εναιωρηματα νανοσωματιδιων που περιεχουν πολυμερες καρβοξυβινυλιου
ES2422458T3 (es) Procedimiento para la producción de un polvo que contiene carotenoides
ATE477283T1 (de) Polymerisierbare zusammensetzungen enthaltend salze aus barbitursäure-derivaten
CL2017001835A1 (es) Una composición fertilizantes y el método de su uso
BR112014033115A2 (pt) pós de polímero solúveis em água com capacidade de dispersão melhorada
JP2008536020A5 (el)
AR092643A1 (es) Microcapsulas secadas por aspersion
BRPI0916299A2 (pt) materias nanocompósitos tridimensionais consistindo de uma matriz polissacarídica e nanopartículas metálicas, preparação e uso dos mesmos
MX2010003506A (es) Particulas generadoras de electricidad y sus usos.
AR085527A1 (es) Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
CL2013001026A1 (es) Particula detergente recubierta teniendo las dimensiones perpendiculares x, y y z, donde x=1 a 2mm, y=2 a 8mm y z=2 a 8mm, que comprende i) 40 a 90% en peso de surfactante anionico o no ionico, presente como nucleo, ii) 1 a 40% de sales inorganicas solubles en agua y iii) 0,0001 a 0,1% de colorantes, ambos presentes como recubrimiento.
EA200800099A1 (ru) Композиции наночастиц мегестрола
BR112013008993A2 (pt) composição detergente particulada
JP2014500802A5 (el)
ECSP088522A (es) Composición farmacéutica sólida que comprende nanopartículas aglomeradas y un proceso de producción de la misma
BR112014002293A2 (pt) processo para a preparação de uma dispersão estável de nanopartículas, dispersão produzida e seu uso
BR112014029635A2 (pt) método para produzir uma partícula compreendendo sulfato
JP2004534074A5 (el)
AR081903A1 (es) Composicion de particulas de detergente envasada
BR112016006901A8 (pt) composição de dentifrício para os cuidados orais e uso de uma composição
JP2010160262A5 (el)
CL2007001713A1 (es) Composicion farmaceutica oral en forma de suspension acuosa que comprende particulas del antihelmintico carbamato de bencimidazol con un 90% de tamano promedio menor que 450 nm y un surfactante polisorbato; metodo para su preparcion; metodo para preparar un medicamento; y uso para controlar infecciones parasitarias en animales.
TH155682A (th) องค์ประกอบซีเมนต์ ซึ่งประกอบรวมด้วยนาโนทิวบ์ชนิดอนินทรีย์ที่ถูกทำให้ไม่ เกาะกลุ่ม และวิธีที่ร่วมด้วย